APA (7th ed.) Citation

Burris, H., Kurkjian, C., Hart, L., Pant, S., Murphy, P., Jones, S., . . . Infante, J. R. (2017). TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemotherapy & Pharmacology, 80(2), 261. https://doi.org/10.1007/s00280-017-3343-4

Chicago Style (17th ed.) Citation

Burris, Howard, et al. "TAK-228 (formerly MLN0128), an Investigational Dual TORC1/2 Inhibitor Plus Paclitaxel, With/without Trastuzumab, in Patients with Advanced Solid Malignancies." Cancer Chemotherapy & Pharmacology 80, no. 2 (2017): 261. https://doi.org/10.1007/s00280-017-3343-4.

MLA (9th ed.) Citation

Burris, Howard, et al. "TAK-228 (formerly MLN0128), an Investigational Dual TORC1/2 Inhibitor Plus Paclitaxel, With/without Trastuzumab, in Patients with Advanced Solid Malignancies." Cancer Chemotherapy & Pharmacology, vol. 80, no. 2, 2017, p. 261, https://doi.org/10.1007/s00280-017-3343-4.